JP2017527614A5 - - Google Patents

Download PDF

Info

Publication number
JP2017527614A5
JP2017527614A5 JP2017531457A JP2017531457A JP2017527614A5 JP 2017527614 A5 JP2017527614 A5 JP 2017527614A5 JP 2017531457 A JP2017531457 A JP 2017531457A JP 2017531457 A JP2017531457 A JP 2017531457A JP 2017527614 A5 JP2017527614 A5 JP 2017527614A5
Authority
JP
Japan
Prior art keywords
pharmaceutical formulation
pharmaceutical preparation
subject
pharmaceutical
kidney disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017531457A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017527614A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/047822 external-priority patent/WO2016036674A1/en
Publication of JP2017527614A publication Critical patent/JP2017527614A/ja
Publication of JP2017527614A5 publication Critical patent/JP2017527614A5/ja
Priority to JP2022180359A priority Critical patent/JP2023011921A/ja
Pending legal-status Critical Current

Links

JP2017531457A 2014-09-02 2015-08-31 重水素化又は非重水素化分子及び医薬製剤 Pending JP2017527614A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022180359A JP2023011921A (ja) 2014-09-02 2022-11-10 重水素化又は非重水素化分子及び医薬製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462044566P 2014-09-02 2014-09-02
US62/044,566 2014-09-02
PCT/US2015/047822 WO2016036674A1 (en) 2014-09-02 2015-08-31 Deuterated or a non-deuterated molecule and pharmaceutical formulations

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2020153867A Division JP2021001193A (ja) 2014-09-02 2020-09-14 重水素化又は非重水素化分子及び医薬製剤
JP2022180359A Division JP2023011921A (ja) 2014-09-02 2022-11-10 重水素化又は非重水素化分子及び医薬製剤

Publications (2)

Publication Number Publication Date
JP2017527614A JP2017527614A (ja) 2017-09-21
JP2017527614A5 true JP2017527614A5 (enExample) 2018-10-11

Family

ID=55401248

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017531457A Pending JP2017527614A (ja) 2014-09-02 2015-08-31 重水素化又は非重水素化分子及び医薬製剤
JP2020153867A Pending JP2021001193A (ja) 2014-09-02 2020-09-14 重水素化又は非重水素化分子及び医薬製剤
JP2022180359A Pending JP2023011921A (ja) 2014-09-02 2022-11-10 重水素化又は非重水素化分子及び医薬製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020153867A Pending JP2021001193A (ja) 2014-09-02 2020-09-14 重水素化又は非重水素化分子及び医薬製剤
JP2022180359A Pending JP2023011921A (ja) 2014-09-02 2022-11-10 重水素化又は非重水素化分子及び医薬製剤

Country Status (9)

Country Link
US (3) US9375408B2 (enExample)
EP (2) EP3628640B1 (enExample)
JP (3) JP2017527614A (enExample)
CN (1) CN106794986A (enExample)
AU (4) AU2015312134A1 (enExample)
CA (1) CA2959965A1 (enExample)
IL (2) IL285760B2 (enExample)
MX (2) MX372723B (enExample)
WO (1) WO2016036674A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006249866B2 (en) 2005-05-26 2011-10-13 Aldeyra Therapeutics, Inc. Compositions and methods of treating retinal disease
WO2011072141A1 (en) 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions and methods for the treatment of macular degeneration
CN117045653A (zh) 2013-01-23 2023-11-14 奥尔德拉医疗公司 与毒性醛相关的疾病和治疗
AU2015312134A1 (en) * 2014-09-02 2017-03-23 Bhupinder Singh Deuterated or a non-deuterated molecule and pharmaceutical formulations
US10550085B2 (en) 2015-08-21 2020-02-04 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
CA3022665A1 (en) 2016-05-09 2017-11-16 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
WO2017218004A1 (en) * 2016-06-17 2017-12-21 Michael Hudnall Medical food for patients with chronic liver disease
CA3054811A1 (en) 2017-03-16 2018-09-20 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US11117907B2 (en) 2017-06-16 2021-09-14 University Of North Florida Board Of Trustees Curcuminoid-inspired synthetic compounds as anti-tumor agents
US10934241B2 (en) * 2017-06-16 2021-03-02 University Of North Florida Board Of Trustees Curcuminoid-inspired synthetic compounds as anti-tumor agents
WO2019075136A1 (en) 2017-10-10 2019-04-18 Aldeyra Therapeutics, Inc. TREATMENT OF INFLAMMATORY DISORDERS
KR20210019459A (ko) 2018-05-24 2021-02-22 레니버스 테라퓨틱스, 인크. 신장 손상 및 신부전 위험이 있는 환자를 치료하는 방법
AU2019319740A1 (en) 2018-08-06 2021-03-25 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US12115138B2 (en) * 2019-03-06 2024-10-15 Renibus Therapeutics, Inc. Tetrahydrocurcumin compositions, methods of making, and methods of using the same
WO2020223717A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
JP2022530967A (ja) 2019-05-02 2022-07-05 アルデイラ セラピューティクス， インコーポレイテッド 多形化合物およびその使用
CA3142023A1 (en) * 2019-05-28 2020-12-03 Case Western Reserve University Compositions and methods for preserving dna methylation
KR20220082092A (ko) * 2019-11-07 2022-06-16 스몰 파마 엘티디 화합물
CN111017878B (zh) * 2019-12-18 2021-12-17 中国原子能科学研究院 一种用于制备平衡态h2-hd-d2标准气体的装置和方法
WO2021138561A1 (en) * 2019-12-31 2021-07-08 Renibus Therapeutics, Inc. Novel tetrahydrocurcumin compositions, methods of making, and methods of using the same
WO2021195124A1 (en) * 2020-03-23 2021-09-30 Renibus Therapeutics, Inc. Stress test and treatment of chronic kidney disease
WO2021231792A1 (en) 2020-05-13 2021-11-18 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
WO2021242872A1 (en) 2020-05-27 2021-12-02 Case Western Reserve University Compositions and methods for preserving dna methylation
CN111759820B (zh) * 2020-08-24 2022-04-19 武汉人福药业有限责任公司 一种奥卡西平片剂及其制备方法
WO2022203674A1 (en) * 2021-03-25 2022-09-29 Majeed, Muhammed Compositions and methods for managing nephropathy

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5276182A (en) 1990-07-09 1994-01-04 The Dow Chemical Company Process for preparing polyurea oligomers
DE4039602A1 (de) 1990-12-12 1992-06-17 Bauer Kurt Heinz Prof Dr Pharmazeutische formulierungen
KR100221695B1 (ko) 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
US5653962A (en) 1991-12-12 1997-08-05 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
AU5612694A (en) 1992-11-27 1994-06-22 Napro Biotherapeutics, Inc. Injectable composition
US5654286A (en) 1993-05-12 1997-08-05 Hostetler; Karl Y. Nucleotides for topical treatment of psoriasis, and methods for using same
EP1475091A1 (en) 1993-10-01 2004-11-10 Roche Palo Alto LLC Mycophenolate mofetil - high dose oral suspensions
US5707641A (en) 1994-10-13 1998-01-13 Pharmaderm Research & Development Ltd. Formulations comprising therapeutically-active proteins or polypeptides
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US5653987A (en) 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US5667809A (en) 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
US6884429B2 (en) * 1997-09-05 2005-04-26 Isotechnika International Inc. Medical devices incorporating deuterated rapamycin for controlled delivery thereof
US6342507B1 (en) 1997-09-05 2002-01-29 Isotechnika, Inc. Deuterated rapamycin compounds, method and uses thereof
JPH11246398A (ja) * 1998-03-02 1999-09-14 Kyowa Hakko Kogyo Co Ltd 生体内過酸化脂質増加に起因する疾患の予防または治療剤
SG149814A1 (en) * 2003-12-19 2009-02-27 Omega Bio Pharma Ip3 Ltd Compositions and methods for treating diabetes
AU2005206163B2 (en) * 2004-01-14 2011-06-30 Gilead Sciences, Inc. Lipid-based dispersions useful for drug delivery
US8841326B2 (en) * 2004-02-12 2014-09-23 Stc.Unm Therapeutic curcumin derivatives
CN1283237C (zh) 2004-11-22 2006-11-08 山东大学 姜黄素磷脂复合物及其制备方法
US7776915B2 (en) * 2005-03-24 2010-08-17 Tracie Martyn International, Llc Topical formulations and methods of use
AU2006274037B2 (en) * 2005-07-26 2012-04-26 Takeda Gmbh Isotopically substituted pantoprazole
EP1934201A1 (en) * 2005-10-06 2008-06-25 Auspex Pharmaceuticals Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
JP2007320864A (ja) * 2006-05-30 2007-12-13 Toshihiko Osawa 非アルコール性脂肪肝炎予防・治療用組成物
JP2008133272A (ja) * 2006-10-31 2008-06-12 Ito En Ltd Ｃｐｔ活性亢進剤及び飲食物
JP2008201768A (ja) * 2006-11-24 2008-09-04 Mizu Kk 抗炎症剤及びシクロオキシゲナーゼ阻害剤
WO2008093848A1 (ja) * 2007-02-02 2008-08-07 Sunstar Inc. ホスファチジルコリンを含有する炎症マーカー低減組成物
WO2010097643A1 (en) * 2009-02-24 2010-09-02 Novatech Istrazivanje D.O.O. Formulation based on micronized zeolite, green tea extract, and genistein as a therapeutic agent for reduction of body weight and cellulite
JP5416472B2 (ja) * 2009-05-07 2014-02-12 株式会社セラバリューズ ウコン色素組成物による心機能改善効果
CN101627969B (zh) * 2009-07-30 2011-06-29 浙江工业大学 一种姜黄素自乳化给药系统及其制备
US20130005824A1 (en) * 2009-10-16 2013-01-03 The Research Foundation Of State University Of New York Treatment of ischemic tissue
CN101732292B (zh) * 2010-01-25 2012-05-16 四川省中医药科学院 四氢姜黄素的用途
CN102526003B (zh) * 2010-01-25 2014-02-19 四川省中医药科学院 四氢姜黄素的用途
WO2011116066A1 (en) * 2010-03-17 2011-09-22 Concert Pharmaceuticals, Inc. Derivatives of dimethylcurcumin
WO2013033250A1 (en) * 2011-09-01 2013-03-07 Xiangping Qian Certain chemical entities, compositions, and methods
CN104739813A (zh) * 2013-12-26 2015-07-01 四川省中医药科学院 四氢姜黄素的新用途
AU2015312134A1 (en) * 2014-09-02 2017-03-23 Bhupinder Singh Deuterated or a non-deuterated molecule and pharmaceutical formulations

Similar Documents

Publication Publication Date Title
JP2017527614A5 (enExample)
Hoang et al. Possible application of high-dose vitamin C in the prevention and therapy of coronavirus infection
Amin et al. Blood pressure‐lowering effect of the sodium glucose co‐transporter‐2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension
JP2015503593A5 (enExample)
Komeili et al. Evaluation of antidiabetic and antihyperlipidemic effects of Peganum harmala seeds in diabetic rats
CN115916772A (zh) 6-氧代-3,6-二氢吡啶类衍生物、其制备方法及其在医药上的应用
FI3750535T3 (fi) Menetelmiä sydän- ja verisuonitautitapahtumien riskin vähentämiseksi tutkittavalla
JP2011516613A5 (enExample)
CA2703834C (en) Silibinin component for the treatment of hepatitis
DeFronzo et al. Once-daily saxagliptin added to metformin provides sustained glycaemic control and is well tolerated over 102 weeks in patients with type 2 diabetes
JP2015522029A5 (enExample)
JP2014533680A5 (enExample)
HRP20131120T1 (hr) Farmaceutski pripravak koji sadrži (1s)-1,5-anhidro-1-[5-(4-etoksibenzil)-2-metoksi-4-metilfenil]-1-tio-d-glucitol i metformin, te njegova uporaba za lijeäśenje dijabetesa
Li et al. Antidiabetic activity of lipophilic (−)-epigallocatechin-3-gallate derivative under its role of α-glucosidase inhibition
JP2021534105A5 (enExample)
JP2014533701A5 (enExample)
Cao et al. Sarcandra glabra extract reduces the susceptibility and severity of influenza in restraint‐stressed mice
Javed et al. Functional Food Industry
WO2017220050A3 (zh) 阿奇霉素的药物组合物及其止咳的医药用途
CN111228248A (zh) 一种治疗肝损伤的药物及花姜酮在制备治疗肝损伤药物方面的应用
Kochhar et al. Yogic Diet and its Anti-inflammatory Effect in Relation to CVD
CN104983727A (zh) 鱼藤酮在制备降低肝脏脂肪沉积药物中的应用
Jawla et al. Isolation of phytoconstituents and antihyperglycemic activity of Bougainvillea spectabilis root bark extracts
Kavadi Role of Sotagliflozin in Managing Heart Failure in Diabetes
Tiwari et al. Role of Nutraceuticals in Addressing Obesity-Related Comorbidities